SteelPeak Wealth LLC Cuts Stock Position in Eli Lilly and Company $LLY

Key Points

• SteelPeak Wealth LLC cut its stake in Eli Lilly (NYSE:LLY) by 30.0% in Q4, selling 1,857 shares and leaving 4,333 shares valued at about $4.657 million per its SEC filing.
• Eli Lilly has major positive catalysts—FDA approval of Foundayo (the first once‑daily oral GLP‑1 for obesity), rapid U.S. commercialization with a planned $6.5B Houston manufacturing plant, and the announced Centessa acquisition—which have prompted mostly bullish analyst coverage and an average price target near $1,222.

SteelPeak Wealth LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 30.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,333 shares of the company's stock after selling 1,857 shares during the period. SteelPeak Wealth LLC's holdings in Eli Lilly and Company were worth $4,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC grew its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares during the last quarter. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at about $29,000. Steph & Co. grew its stake in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company's stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. 10Elms LLP grew its stake in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. Finally, Miller Global Investments LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Foundayo, the first once-daily oral GLP‑1 for obesity; Lilly has begun rapid U.S. commercialization and analysts see a multi‑billion-dollar revenue opportunity that helps close the gap with rivals. How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
• Positive Sentiment: Production capacity ramp: Lilly will manufacture the new oral GLP‑1 at a $6.5B Houston plant, reducing supply risk and supporting commercialization scale-up. This is a tangible capex commitment to grow supply for Foundayo. Eli Lilly's $6.5B Houston plant will make its new FDA-approved GLP-1 weight loss drug
• Positive Sentiment: Access agreement and M&A broaden growth runway: Lilly announced a U.S. pricing/access arrangement to expand Medicare/Medicaid availability for GLP‑1s and is acquiring Centessa (~$7.8B) to add sleep and neuroscience assets — both support longer‑term revenue diversification. Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
• Positive Sentiment: Investor sentiment lift: Several bullish notes and price-target increases have followed the Foundayo approval, reinforcing upside case for long‑term revenue and margin expansion. Eli Lilly and Company NYSE: LLY Price Target Raised to $1,294.00
• Neutral Sentiment: Sector M&A/AI tailwinds: Pharma and biotech are accelerating M&A and AI-driven R&D investments; Lilly is participating to both defend and extend its pipeline — positive strategically but benefits will play out over quarters. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Neutral Sentiment: Market narrative around AI and a race to a $1T market cap keeps bullish storytelling alive, but share-price milestones remain dependent on sustained revenue/margin execution and pricing environment. Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?
• Negative Sentiment: Price competition concerns: Coverage notes a nascent price war in the oral GLP‑1 category that could cap near‑term revenue/margin upside even after approval, pressuring the immediate stock reaction. StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod
• Negative Sentiment: Analyst repositioning: Some research shops have adjusted ratings/positions post-approval (e.g., reclassifications to Buy vs. Strong Buy), suggesting near-term profit‑taking or more cautious multiple expansion assumptions. Eli Lilly and Company NYSE: LLY Downgraded to "Buy" Rating by Wall Street Zen

Wall Street Analyst Weigh In

Several equities analysts have issued reports on LLY shares. Guggenheim cut their target price on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the company a "buy" rating in a research note on Friday, March 13th. Morgan Stanley reiterated an "overweight" rating and issued a $1,313.00 target price on shares of Eli Lilly and Company in a research note on Thursday, March 5th. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a research note on Thursday, January 29th. Finally, Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,222.22.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $925.93 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a market capitalization of $874.84 billion, a price-to-earnings ratio of 40.35, a PEG ratio of 1.09 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock's 50-day simple moving average is $990.91 and its 200-day simple moving average is $972.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the firm earned $5.32 earnings per share. The company's revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.